To amend the Federal Food, Drug, and Cosmetic Act and Public Health Service Act to advance the next-generation of clinical development of novel treatments and cures, and for other purposes.
Key claim: A newly introduced House bill would change FDA and public-health law to modernize how new treatments and cures are developed and tested in clinical trials.
Abstract
(HR10857 · 119th Congress) Latest action (2026-10-22): Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Why this matters
Clinical development rules under the FD&C Act and PHSA determine how quickly and under what evidence standards new treatments reach patients. A bill broadly framed around modernizing these pathways signals congressional interest in revising trial design, evidence requirements, or FDA review processes, though the practical effect on patients, sponsors, and reviewers cannot be assessed until legislative text and provisions become available.